RBC Capital Reiterates Outperform on Ionis Pharmaceuticals, Maintains $65 Price Target
Portfolio Pulse from Benzinga Newsdesk
RBC Capital analyst Luca Issi has reiterated an 'Outperform' rating on Ionis Pharmaceuticals (NASDAQ:IONS) and maintained a $65 price target.
October 05, 2023 | 4:03 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
RBC Capital has reiterated an 'Outperform' rating on Ionis Pharmaceuticals and maintained a $65 price target, indicating a positive outlook for the company.
The reiteration of an 'Outperform' rating by RBC Capital indicates that the analyst believes Ionis Pharmaceuticals will outperform the market. This, coupled with the maintained price target of $65, suggests a positive outlook for the company's stock in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100